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A divergent synthesis to generate targeted libraries of 
inhibitors for endo-N-acetylglucosaminidases
Isaac K. Seo, Esther H. Woo, Samy Cecioni, and David J. Vocadlo
Abstract: Cell active inhibitors of glycoside processing enzymes are valuable research tools that help us understand the physiological 
roles of this diverse class of enzymes. endo-N-Acetylglucosaminidases have gained increased attention for their important roles in both 
mammals and human pathogens; however, metabolically stable cell active inhibitors of these enzymes are lacking. Here, we describe a 
divergent synthetic strategy involving elaboration of a thiazoline core scaffold. We illustrate the potential of this approach by using the copper 
catalysed azide-alkyne click (CuAAC) reaction, in combination with a suitable catalyst to avoid poisoning by the thiazoline moiety, to generate a 
targeted panel of candidate inhibitors of endo-N-acetylglucosaminidases and chitinases.
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Résumé : Les inhibiteurs d’enzymes de transformation des glycosides actifs en milieu cellulaire constituent des outils de recherche précieux qui 
aident à comprendre les rôles physiologiques de cette classe diversifiée d’enzymes. On a découvert que les endo-N-acétylglucosaminidases 
jouaient un rôle important chez les pathogènes affectant tant les mammifères que les hu-mains. Cependant, on ne dispose pas d’inhibiteurs de 
ces enzymes qui soient stables et actifs en milieu cellulaire. Dans le présent article, nous décrivons une stratégie de synthèse divergente faisant 
intervenir l’élaboration d’une structure centrale à base de thiazoline. Au moyen d’une réaction catalysée par le cuivre de type « clic » entre un 
azoture et un alcyne dans laquelle nous avons employé un catalyseur compatible afin d’éviter qu’il soit empoisonné par le fragment thiazoline, 
nous illustrons le potentiel de cette approche pour générer une série ciblée de composés susceptibles d’inhiber les endo-N-
acétylglucosaminidases et les chitinases. [Traduit par la Rédaction]
Mots-clés : inhibiteur enzymatique, glucosaminidase, catalyse assistée par le substrat, thiazoline.
Introduction
endo-N-Acetylglucosaminidases, including chitinases and hyalu-
ronidases, are responsible for hydrolyzing the glycosidic bonds of
2-acetamido-2-deoxy--D-glucopyranose (GlcNAc) residues found
within oligosaccharides and polysaccharides.1 These enzymes,
along with muramidases, which process structurally related
2-acetamido-2-deoxy-3-O-lactyl--D-glucopyranose (MurNAc) resi-
dues found within the peptidoglycan of bacterial cell walls, play
diverse roles in biology, e.g., remodeling of the ECM inmetazoans,
controlling bacterial cell wall structure, and regulating insect and
parasite maturation.2,3 All of these families of enzymes are struc-
turally distinctive and are accordingly distributed among distinct
families of glycoside hydrolases (GHs), including GH18,4,5 GH22,6,7
GH25,8 GH56,9 GH73,10,11 and GH8512,13 of the CAZy classification
system.14 Of these families of enzymes, GH18, GH56, GH73, and
GH85 use a catalytic mechanism involving neighbouring group
participation of the 2-acetamido group. This substrate assisted
catalytic mechanism has been well defined, particularly for exo-
acting -glucosaminidases from families GH2015–17 and GH84.18–22
In this two-step double displacement mechanism (Fig. 1), the
amide carbonyl of the 2-acetamido group is oriented and polar-
ized by a hydrogen bond between the amide nitrogen and an
enzymic carboxylate residue. The first step of this mechanism
involves attack of the carbonyl group on the anomeric carbon,
which aids concomitant expulsion of the leaving group alcohol in
a process that is facilitated by an enzymic general acid catalytic
residue. The resulting oxazoline intermediate is hydrolyzed in a
second enzyme catalyzed step that is the nearmicroscopic reverse
of the first step, differing principally in that a molecule of water
takes the place of the leaving group. Such oxazoline intermedi-
ates have recently been observed directly within the active site of
GH84 enzymes,21 and stable thiazoline-based analogues of these
oxazolines, including 1,2-dideoxy-2=-ethyl--D-glucopyranoso-[2,1-d]-
2=-thiazoline (NAG-thiazoline)18,23 and more potent derivatives
such as Thiamet-G,24,25 have been found to be potent inhibitors of
GH84 enzymes. Such inhibitors have been found to be transition
state analogues,26 which contributes to their generally high inhib-
itor potencies, which show picomolar Ki values in some cases.
27
Despite the potency of such thiazoline-based inhibitors, limited
effort has focused on creating such inhibitors for endo-acting
enzymes from these families. Notably, NAG-thiazoline containing
oligosaccharide inhibitors of GH20 chitinases28 and GH85 endo-N-
acetylglucosaminidases29 show strong inhibition of these enzymes
(Fig. 1). These oligosaccharide-derived inhibitors are, however,
susceptible to processing by other glycoside hydrolases that can
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trim off the nonreducing residues. Because they are also com-
prised of natural saccharide units, it is difficult to improve their
physicochemical properties to make them more suitable for use
in cells or in vivo. We were stimulated by these observations to
develop a strategy enabling parallel synthesis to generate a panel
of inhibitors of endo-acting enzymes that use a substrate assisted
catalytic mechanism. Notably, the structures of GH18,30,31 GH56,9
and GH8532–34 enzymes reveal cleft-shaped active site architec-
tures in which aromatic amino acid side chains act to bind saccha-
ride residues at the nonreducing end within a series of subsites.
Therefore, we reasoned that appending aryl substituents to the
4-hydroxyl group of the thiazoline-containing residue bound in
the –1 subsite could enable these aryl groups to take the position
of sugar residues of the oligosaccharide chain boundwithin the –2
and –3 subsites.
Relatively limited chemistry has been applied to derivatization
of NAG-thiazoline at its various hydroxyl groups29,35 The similar
reactivity of the 3- and 4-hydroxyl positions of gluco-configured
saccharides,36 coupled with the sensitivity of the thiazoline moiety
towards oxidative, reductive, radical, and acidic conditions,37–39 has
likely hindered the development of such chemistries. Accord-
ingly, to advance on our goal, we describe here a method to
selectively alkylate NAG-thiazoline at the 4-position. Late stage
propargylation of a common deprotected intermediate, in partic-
ular, allowed us to use the copper catalysed azide-alkyne click
(CuAAC) reaction to rapidly assemble a targeted panel of inhibi-
tors for GH18 and GH85 enzymes.
Experimental
General
All commercially available chemicals were purchased from
Sigma-Aldrich, Alfa Aesar, Carbosynth, or TCI and used without
further purification. Noncommercial azides were purchased from
Peng Wu at the Scripps Research Institute. All dry solvents were
purchased from Sigma-Aldrich or VWR and used without further
purification. The progress of all reactions was monitored via thin
layer chromatography on Merck pre-coated silica gel plates using
ethyl acetate/hexanes, ethyl acetate/dichloromethane, methanol/
dichloromethane, or acetone/hexanes solvent elution systems.
Flash chromatography was performed under positive pressure
using Fisher Scientific silica gel (230–400 mesh) where spots were
visualized under ultraviolet light (254 nm) and staining with
KMnO4 and gentle heating. Proton (
1H) and carbon (13C) spectra
were obtained on either a Bruker AVANCE 500 (500 MHz for 1H,
125 MHz for 13C) or a Bruker AVANCE 400 (400 MHz for 1H,
100 MHz for 13C) unless otherwise specified. NMR samples were
dissolved in deuterated chloroform, methanol, or DMSO from
Cambridge Isotope Laboratories. High resolution mass spectros-
copy data was obtained using a Bruker maXis TOF LC/MS/MS in-
strument.
Procedure for the synthesis of 3,6-O-dipivaloyl-NAG-thiazoline 2
NAG-thiazoline (1.80 g, 8.66mmol), prepared from glucosamine
hydrochloride,23 was added to a 250 mL flame-dried, round-
bottom flask under an atmosphere of argon. NAG-thiazoline,
along with DMAP (100 mg, 0.9 mmol), was dissolved in pyridine
Fig. 1. (A) Mechanism of substrate-assisted catalysis, (B) NAG-thiazoline 1, (C) chitotriose-thiazoline inhibitor of chitinase, and 
(D) Man3GlcNAc-thiazoline inhibitor of endo-beta-glucosamindase-A from Arthrobacter protophormiae. [Colour online.]
(100 mL), and pivaloyl chloride (2.1 mL, 17.0 mmol) was added
dropwise to the resulting solution, which had been cooled to 0 °C.
Once this addition was complete, the reaction mixture was al-
lowed to warm to room temperature and left stirring for 16 h.
Upon completion, the solution was concentrated under vacuum
to one-fifth of the original volume by co-evaporationwith toluene.
Ethyl acetate (200 mL) was added, and the organic layer was
washed five times with water. The resulting organic layer was
further washed with a saturated aqueous solution of potassium
bisulfate until no pyridinium bisulfate precipitates were observed.
Theorganic fractionwas thendriedover sodiumsulfate beforebeing
filtered and concentrated in vacuo. Purification by silica gel flash
column chromatography (2:3 ethyl acetate:hexanes) yielded
equimolar amounts of 1,2-dideoxy-2=-ethyl-3,6-di-O-pivaloyl--D-
glucopyranoso-[2,1-d]-2=-thiazoline (3,6-O-dipivaloyl-NAG-thiazoline)
2 and 1,2-dideoxy-2=-ethyl-4,6-di-O-pivaloyl--D-glucopyranoso-
[2,1-d]-2=-thiazoline (4,6-O-dipivaloyl-NAG-thiazoline) 3 as clear
colourlessgums (1.10g foreach,33%) alongwith 1,2-dideoxy-2=-ethyl-6-O-
pivaloyl--D-glucopyranoso-[2,1-d]-2=-thiazoline (6-O-pivaloyl-
NAG-thiazoline) 4 (762 mg, 29%).
Procedure for recycling 4,6-O-dipivaloyl-NAG-thiazoline 3
The undesired 4,6-O-dipivaloyl-NAG-thiazoline 3 (1.00 g, 2.58 mmol)
was added to a 100 mL flame-dried, round-bottom flask under an
atmosphere of argon. The compound was dissolved in methanol
(50 mL), and the mixture was cooled on ice before adding suffi-
cient solid sodium methoxide such that the pH value of the
solution reached 10. Themixture was left stirring at room temper-
ature for 16 h. Upon completion of the reaction, acetic acid was
added dropwise until the pH value of the solution was neutral.
The solvent was removed in vacuo, and dichloromethane (400mL)
was added to the residue, which was triturated. The resulting
suspension was filtered, and the solid was washed with dichlo-
romethane. The filtrate was concentrated and purified by silica
gel flash column chromatography (1:9 methanol:dichlorometh-
ane) to yield NAG-thiazoline (413 mg, 73%).
Procedure for synthesis of 3,6-O-dipivaloyl-4-O-propargyl-
NAG-thiazoline 5
3,6-O-Dipivaloyl-NAG-thiazoline 2 (200 mg, 0.516 mmol) was
added to a 100 mL flame-dried, round-bottom flask under an at-
mosphere of argon. The compound was dissolved in anhydrous
DMF (25 mL) and cooled in a dry ice – brine bath at –20 °C. Sodium
hydride (42 mg, 1.04 mmol, 60% dispersion in mineral oil) was
slowly added in small portions over 5 min, and the resulting mix-
ture was left to stir for 10 min. Propargyl bromide (974 L,
1.04 mmol, 80% in toluene) was then added dropwise by syringe,
and the resulting reaction mixture was stirred at –20 °C for 6 h
after which it was warmed to 0 °C and allowed to then stir for 4 h.
Ethyl acetate was next added to the reaction mixture, and the
solution was washed five times with water, followed by back ex-
traction of the aqueous layer with ethyl acetate. The combined
organic layers were washed eight times with water and brine to
remove residual DMF. The remaining solvent was dried over
Na2SO4, filtered, and concentrated in vacuo to yield a gummy
residue. The residue was subjected to silica gel flash column
chromatography (1:4 ethyl acetate:hexanes) to afford 1,2-dideoxy-
2=-ethyl-3,6-di-O-pivaloyl-4-O-propynyl--D-glucopyranoso-[2,1-d]-
2=-thiazoline (3,6-O-dipivaloyl-4-O-propargyl-NAG-thiazoline) 5
as a clear, colourless gum (129 mg, 59%). A small amount of
pivaloyl migration was observed with the formation of the 3-O-
propargyl derivative (26 mg, 10%).
Procedure for synthesis of 4-O-propargyl-NAG-thiazoline 6
3,6-O-Dipivaloyl-4-O-propargyl-NAG-thiazoline 5 was added to a
50 mL flame-dried, round-bottom flask under an atmosphere of
argon. The compound was dissolved in methanol, after which
sufficient 10% w/w methanolic solution of sodiummethoxide was
added to render the pH value of the reaction mixture basic (pH =
10), and the mixture was then allowed to stir for 16 h at room
temperature. The mixture was cooled to 0 °C, and then, dilute
acetic acid, inmethanol, was added to neutralize themixture. The
solvent was then removed under vacuum, the resulting residue
triturated using DCM, and filtered. The filtrate was concentrated
in vacuo and purified via silica gel flash column chromatography
(1:19 methanol:DCM) to afford 1,2-dideoxy-2=-ethyl-4-O-propynyl-
-D-glucopyranoso-[2,1-d]-2=-thiazoline (4-O-propargyl-NAG-thiazoline)
6 as a white foam (quantitative).
General procedure for synthesis of 4-O-(aryl-1-H–1,2,3-triazol-
4-yl)methyl-NAG-thiazolines 7–14 and 4-O-(alkyl-1-H–1,2,3-triazol-
4-yl)methyl-NAG-thiazolines 15–24
4-O-propargyl-NAG-thiazoline 6 (13 mg, 0.0505 mmol), copper
sulfate (8 mg, 0.032 mmol), sodium ascorbate (10 mg, 0.05 mmol),
2-(4-((bis((1-(tert-butyl)-1H-1,2,3-triazol-4-yl)methyl)amino)methyl)-
1H-1,2,3-triazol-1-yl)acetic acid (BTTAA) (1.0 mg, 2.3 mol), and the
desired azide (0.056 mmol) were added to a 50 mL round-bottom
flask and dissolved in a mixture of t-butanol (2 mL) and water
(500 L). The reaction mixture was stirred for 3 h. Upon comple-
tion, the solvent was removed in vacuo by azeotropewith ethanol,
and the desiredmaterial was purified from the residue using silica
gel flash column chromatography (1:19 methanol:DCM) to afford
4-O-(aryl-1-H–1,2,3-triazol-4-yl)methyl-NAG-thiazolines 7–14 and
4-O-(alkyl-1-H–1,2,3-triazol-4-yl)methyl-NAG-thiazolines 15–24 as a
clear white foams (47%–91%). For details on yields, please see
Table 1, and for the corresponding structures of all compounds,
please see the Supplementary data.
General procedure for synthesis of 4-azido benzamides 25–29
4-azidobenzoic acid (20 mg, 0.123 mmol) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDCI) (26 mg, 0.135 mmol)
were added to a 50 mL flame-dried round-bottom flask under an
atmosphere of argon. The compounds were dissolved in chlo-
roform (10 mL), then TEA (14 L, 0.135 mmol) and amine
(200 mmol) were added. The reaction mixture was heated and
maintained at refluxed for 16 h. Upon completion of the reaction,
the solvent was removed in vacuo, and the title compound was
purified by silica gel flash column chromatography (3:7 ethyl
acetate:hexanes) to afford 4-azido-N-alkylbenzamides 25–29 as a
clear colourless liquid (54%–89%). For details on yields please see
Table 1. Synthesis of a targeted
panel of 4-(alkyl/aryl-1-H-1,2,3-triazol-
4-yl)methyl-NAG-thiazoline deriva-
tives via CuAAC reaction in the
presence of BTTAA catalyst.
Compound Isolated yield (%)
7 59
8 63
9 42
10 60
11 71
12 64
13 82
14 68
15 81
16 41
17 38
18 47
19 56
20 73
21 39
22 54
23 53
24 91
Table 2 and for the corresponding structures of all compounds
please see the Supplementary data.
Spectral data analysis for compounds
For structures of numbered compounds, please see the Supple-
mentary data.
Compound 2
1H NMR (400 MHz, Chloroform-d) H 6.33 (d, J = 7.3 Hz, 1H), 4.75
(ddd, J = 9.1, 2.7, 0.9 Hz, 1H), 4.48 (m, 1H), 4.33 (t, J = 3.1 Hz, 1H), 4.16
(dd, J = 12.0, 2.7 Hz, 1H), 4.11 (dd, J = 12.0, 6.1 Hz, 1H), 3.65 (ddd, J =
8.8, 6.0, 2.7 Hz, 1H), 2.26 (d, J = 2.0 Hz, 3H), 1.19 (s, 18H). 13C NMR
(100 MHz, Chloroform-d) c 178.23, 178.21, 167.29, 89.43, 79.31,
71.93, 70.56, 69.43, 63.39, 38.97, 38.83, 36.78, 27.29, 27.09, 24.81,
20.79. HRMS (ESI+) m/z: [M + H]+ calcd for C18H30NO6S, 388.1794;
found, 388.1817.
Compound 5
1H NMR (400 MHz, Chloroform-d) H 6.27 (d, J = 7.3 Hz, 1H), 4.82
(d, J = 8.0 Hz, 1H), 4.54 (m, 1H), 4.41 (d, J = 2.7 Hz, 2H), 4.30 (m, 1H),
4.14 (dd, J = 12.1, 2.5 Hz, 1H), 4.03 (dd, J = 12.0, 6.5 Hz, 1H), 3.53 (ddd,
J = 8.9, 6.6, 2.3 Hz 1H), 2.42 (t, J = 2.1 Hz, 1H), 2.27 (d, J = 2.4 Hz, 1H),
1.20 (s, 9H), 1.10 (s, 9H). 13C NMR (100MHz, Chloroform-d) c 178.25,
177.28, 88.78, 79.24, 75.01, 74.76, 69.28, 63.36, 57.21, 38.96, 39.91,
27.35, 27.15, 20.72. HRMS (ESI+) m/z: [M + H]+ calcd for C21H32NO6S,
426.1950; found, 426.1942.
Compound 6
1H NMR (400 MHz, Chloroform-d) H 6.34 (d, J = 6.0 Hz, 1H),
4.45–4.40 (m, 2H), 4.31 (dd, J = 16.1, 2.4 Hz, 1H), 4.25 (dd, J = 16.0,
2.4 Hz, 1H), 3.73 (dd, J = 12.2, 2.0 Hz, 1H), 3.60–3.52 (m, 2H), 3.22 (m,
1H), 2.87 (t, J = 3.1 Hz, 1H), 2.27 (d, J = 2.0 Hz, 1H). 13C NMR (126 MHz,
Methanol-d)  170.81, 89.98, 89.83, 80.59, 80.54, 80.48, 80.43, 76.22,
75.99, 73.98, 69.47, 69.41, 63.61, 57.76, 57.64, 20.22, 20.18. HRMS
(ESI+) m/z: [M + H]+ calcd for C11H16NO4S, 258.0800; found,
258.0789.
Compound 7
1H NMR (400 MHz, Methanol-d4)  8.24 (s, 1H), 7.80–7.70 (m, 4H),
6.34 (d, J = 6.4 Hz, 1H), 5.49 (s, 0H), 4.47–4.39 (m, 2H), 4.35–4.20 (m,
2H), 3.73 (dd, J = 12.1, 2.4 Hz, 1H), 3.64–3.50 (m, 2H), 3.22 (ddd, J =
9.1, 6.6, 2.3 Hz, 1H), 2.27 (d, J = 1.9 Hz, 3H). 13C NMR (125 MHz,
Methanol-d4)  167.07, 148.19, 134.15, 130.76, 130.22, 121.16, 119.75,
78.64, 76.41, 75.12, 75.00, 70.66, 62.12, 59.29, 19.67. HRMS (ESI+)
m/z: [M + H]+ calcd for C17H20ClN4O4S, 411.0894; found, 411.0891.
Compound 8
1H NMR (400 MHz, Methanol-d4)  8.39 (s, 1H), 7.82–7.69 (m, 1H),
7.69–7.48 (m, 3H), 6.38 (d, J = 7.0 Hz, 1H), 4.97 (d, J = 12.4 Hz, 1H),
4.79 (d, J = 12.4 Hz, 1H), 4.57 (dd, J = 3.7, 2.0 Hz, 1H), 4.52–4.45 (m,
1H), 3.68–3.58 (m, 2H), 3.57–3.45 (m, 1H), 3.32–3.27 (m, 1H), 2.28 (d,
J = 2.1 Hz, 3H). 13C NMR (125 MHz, Methanol-d4)  167.07, 148.31,
136.54, 131.86, 127.91, 127.88, 127.67, 120.89, 120.34, 78.64, 76.41,
75.12, 75.00, 70.66, 62.12, 59.51, 19.67. HRMS (ESI+) m/z: [M + H]+
calcd for C17H20ClN4O4S, 411.0894; found, 411.0891.
Compound 9
1H NMR (500MHz, Chloroform-d)  8.35 (s, 1H), 7.96–7.81 (m, 2H),
7.79–7.59 (m, 2H), 6.16 (d, J = 2.4 Hz, 1H), 4.80–4.62 (m, 2H), 4.54 (d,
J = 12.1 Hz, 1H), 4.45 (tdd, J = 8.0, 6.9, 1.9 Hz, 1H), 4.10–3.96 (m, 2H),
3.86 (dt, J = 12.1, 5.3 Hz, 2H), 3.81 (s, 3H), 3.70–3.61 (m, 1H), 3.57–3.50
(m, 3H), 2.34 (d, J = 1.5 Hz, 3H), 1.98 (t, J = 5.3 Hz, 4H). 13C NMR
(125 MHz, Chloroform-d)  171.03, 167.07, 148.19, 138.02, 134.47,
129.00, 119.75, 119.19, 106.05, 78.64, 76.41, 75.12, 75.00, 70.66, 64.33,
62.12, 59.29, 41.44, 35.38, 19.67. HRMS (ESI+) m/z: [M + H]+ calcd for
C25H32N5O7S, 546.2022; found, 546.2021.
Compound 10
1H NMR (500 MHz, Methanol-d) 7.87 (dd, J = 8.5, 1.6 Hz, 2H), 6.90
(dd, J = 8.5, 1.6 Hz, 2H), 6.15 (d, J = 7.5 Hz, 1H), 4.36 (q, J = 4.6, 3.2 Hz,
2H), 4.30–4.12 (m, 2H), 3.71 (dd, J = 14.2, 2.7 Hz, 2H), 3.62–3.46 (m,
2H), 3.22 (m, 1H), 2.33 (d, J = 2.2 Hz, 3H). 13C NMR (125 MHz,
Methanol-d)  167.07, 166.17, 148.19, 138.65, 130.97, 128.15, 119.75,
118.98, 78.64, 76.41, 75.12, 75.00, 70.66, 62.12, 59.29, 52.17, 19.67.
HRMS (ESI+) m/z: [M + H]+ calcd for C19H23N4O6S, 435.1338; found,
435.1339.
Compound 11
1H NMR (400 MHz, Chloroform-d)  7.92–7.73 (m, 2H), 7.45–7.25
(m, 5H), 7.18–7.02 (m, 2H), 6.45 (s, 1H), 6.36 (d, J = 6.3 Hz, 1H), 4.66
(d, J = 5.6 Hz, 2H), 4.51–4.40 (m, 2H), 4.35–4.18 (m, 2H), 3.75 (dd, J =
12.1, 2.3 Hz, 1H), 3.64–3.50 (m, 2H), 3.24 (ddd, J = 9.0, 6.6, 2.3 Hz, 1H),
2.29 (d, J = 1.9 Hz, 3H). 13C NMR (125 MHz, Chloroform-d)  167.66,
167.07, 148.19, 138.71, 137.75, 132.77, 128.89, 128.40, 127.31, 127.17,
119.75, 119.13, 78.64, 76.41, 75.12, 75.00, 70.66, 62.12, 59.29, 43.79,
19.67. HRMS (ESI+) m/z: [M + H]+ calcd for C25H28N5O5S, 510.1811;
found, 510.1818.
Compound 12
1H NMR (500 MHz, Chloroform-d)  7.87–7.73 (m, 5H), 6.55 (t, J =
4.4 Hz, 1H), 6.26 (d, J = 2.4 Hz, 1H), 4.74 (d, J = 12.1 Hz, 1H), 4.69–4.54
(m, 2H), 4.21 (tdd, J = 8.3, 6.9, 2.0 Hz, 1H), 3.98 (ddd, J = 11.9, 7.1,
5.7 Hz, 1H), 3.90 (qd, J = 5.7, 2.0 Hz, 1H), 3.77–3.72 (m, 1H), 3.55–3.38
(m, 4H), 2.36 (s, 3H), 1.23 (t, J = 7.1 Hz, 3H). 13C NMR (125 MHz,
Chloroform-d)  167.70, 167.07, 148.19, 137.75, 132.37, 128.89,
119.75, 119.13, 78.64, 76.41, 75.12, 75.00, 70.66, 62.12, 59.29, 35.96,
19.67, 14.66. HRMS (ESI+) m/z: [M + H]+ calcd for C20H26N5O5S,
448.1655; found, 448.1641.
Compound 13
1H NMR (400MHz,Methanol-d)  7.90–7.68 (m, 2H), 7.21–6.97 (m,
2H), 6.36 (d, J = 6.4 Hz, 1H), 6.15 (s, 1H), 4.52–4.37 (m, 2H), 4.37–4.17
(m, 2H), 3.75 (dd, J = 12.1, 2.3 Hz, 1H), 3.60–3.51 (m, 2H), 3.47 (td, J =
7.2, 5.7 Hz, 2H), 3.24 (dd, J = 15.8, 2.3 Hz, 1H), 2.29 (d, J = 1.8 Hz, 3H),
1.62 (tt, J = 7.8, 6.4 Hz, 2H), 1.53–1.35 (m, 2H), 0.98 (t, J = 7.3 Hz, 3H).
13C NMR (125 MHz, Methanol-d)  168.77, 167.07, 148.19, 137.75,
128.89, 126.87, 119.75, 119.13, 78.64, 76.41, 75.12, 75.00, 70.66, 62.12,
59.29, 40.10, 30.74, 20.43, 19.67, 13.74. HRMS (ESI+) m/z: [M + H]+
calcd for C22H30N5O5S, 476.1968; found, 476.1964.
Compound 14
1H NMR (400MHz, Methanol-d)  7.83–7.70 (m, 2H), 7.32–7.19 (m,
5H), 7.10–7.00 (m, 2H), 6.36 (d, J = 6.4 Hz, 1H), 6.31 (d, J = 7.7 Hz, 1H),
4.96 (qt, J = 7.2, 4.3 Hz, 1H), 4.45 (dp, J = 6.0, 2.0 Hz, 2H), 4.37–4.23
(m, 2H), 3.75 (dd, J = 12.1, 2.3 Hz, 1H), 3.66–3.52 (m, 2H), 3.44 (dd, J =
16.3, 7.1 Hz, 2H), 3.24 (ddd, J = 9.0, 6.6, 2.3 Hz, 1H), 2.95 (dd, J = 16.2,
4.4 Hz, 2H), 2.28 (d, J = 2.0 Hz, 3H). 13C NMR (100 MHz, Methanol-d)
 170.79, 167.07, 148.19, 138.30, 137.84, 134.58, 128.70, 127.77, 127.41,
119.75, 119.22, 78.64, 76.41, 75.12, 75.00, 70.66, 62.12, 59.29, 51.48,
35.93, 19.67. HRMS (ESI+) m/z: [M + H]+ calcd for C26H30N5O5S,
524.1968; found, 524.1966.
Compound 15
1H NMR (500 MHz, Chloroform-d)  7.57 (s, 1H), 7.40 (t, J = 5.4 Hz,
5H), 6.46 (s, 1H), 5.54 (s, 2H), 4.85 (d, J = 6.8 Hz, 1H), 4.54 (s, 1H), 4.45
(s, 1H), 3.85 (d, J = 7.8 Hz, 2H), 3.73 (dd, J = 23.2, 5.1 Hz, 3H), 3.46 (s,
1H), 2.34 (s, 3H). 13C NMR (125 MHz, Chloroform-d)  169.07, 149.50,
139.18, 132.31, 132.07, 124.76, 120.53, 78.64, 76.41, 75.12, 75.00,
Table 2. Synthesisof4-azidobenza-
mides.
Compound Isolated yield (%)
25 76
26 89
27 76
28 54
29 67
70.66, 62.12, 59.23, 52.53, 19.67. HRMS (ESI+) m/z: [M + H]+ calcd for
C18H23N4O4S, 391.1440; found, 391.1438.
Compound 16
1H NMR (500MHz, Chloroform-d)  7.59–7.48 (m, 2H), 7.41 (s, 1H),
7.19–7.09 (m, 2H), 6.05 (d, J = 2.4 Hz, 1H), 5.62 (d, J = 11.2 Hz, 1H), 5.44
(d, J = 11.2 Hz, 1H), 4.71 (d, J = 12.1 Hz, 1H), 4.54 (d, J = 11.9 Hz, 1H), 4.28
(dd, J = 8.2, 2.4 Hz, 1H), 4.18 (m, 1H), 3.91 (m, 1H), 3.80–3.71 (m, 1H),
3.68–3.54 (m, 2H), 2.37 (d, J = 1.5 Hz, 3H). 13C NMR (125 MHz,
Chloroform-d)  167.07, 148.88, 145.00, 140.68, 136.38, 123.42,
122.16, 120.27, 116.57, 114.38, 78.64, 76.41, 75.12, 75.00, 70.66, 62.12,
59.23, 45.87, 19.67. HRMS (ESI+) m/z: [M + H]+ calcd for
C19H23N6O4S, 431.1502; found, 431.1509.
Compound 17
1H NMR (500 MHz, Chloroform-d)  9.30 (dd, J = 1.5, 0.7 Hz, 1H),
8.37 (s, 1H), 7.58–7.47 (m, 2H), 5.87 (d, J = 2.4 Hz, 1H), 5.71 (d, J =
11.3 Hz, 1H), 5.44 (d, J = 11.4 Hz, 1H), 4.56 (d, J = 11.9 Hz, 1H), 4.32 (d,
J = 11.9 Hz, 1H), 4.11 (dd, J = 8.3, 2.4 Hz, 1H), 4.06–3.96 (m, 1H), 3.71
(m, 1H), 3.61 (m, 1H), 3.53–3.39 (m, 2H), 2.21 (d, J = 1.6 Hz, 3H), 1.29
(s, 9H). 13C NMR (125 MHz, Chloroform-d)  167.07, 152.71, 152.58,
146.50, 142.46, 133.79, 125.34, 124.31, 120.61, 79.88, 78.64, 76.41,
75.12, 75.00, 70.66, 62.12, 59.23, 51.98, 28.11, 19.67. HRMS (ESI+)m/z:
[M + H]+ calcd for C22H31N6O6S, 507.2026; found, 507.2022.
Compound 18
1H NMR (500MHz, Chloroform-d)  8.65 (s, 1H), 7.87–7.75 (m, 1H),
7.53–7.40 (m, 2H), 6.74 (m, 1H), 5.17 (d, J = 2.4 Hz, 1H), 4.35 (d, J =
12.1 Hz, 1H), 4.21 (m, 1H), 4.19–4.04 (m, 3H), 4.04–3.95 (m, 1H), 3.42
(m, 1H), 3.36–3.27 (m, 1H), 3.27–3.10 (m, 2H), 2.54 (dd, J = 14.1,
7.7 Hz, 1H), 2.51–2.39 (m, 1H), 1.97 (d, J = 1.5 Hz, 3H). 13C NMR
(125 MHz, Chloroform-d)  170.12, 167.07, 153.15, 147.71, 142.95,
137.86, 122.68, 118.60, 114.33, 78.64, 76.41, 75.12, 75.00, 70.66, 62.12,
59.23, 45.14, 37.18, 19.67. HRMS (ESI+) m/z: [M + H]+ calcd for
C19H25N6O5S, 449.1607; found, 449.1599.
Compound 19
1H NMR (500 MHz, Chloroform-d)  7.83 (d, J = 8.4 Hz, 1H), 7.69–
7.63 (m, 1H), 7.59 (s, 1H), 7.55 (d, J = 2.2 Hz, 1H), 7.38 (dd, J = 8.0,
1.5 Hz, 1H), 7.18 (dd, J = 8.4, 2.2 Hz, 1H), 5.57 (d, J = 2.4 Hz, 1H), 5.44
(d, J = 15.2 Hz, 1H), 5.17 (d, J = 15.2 Hz, 1H), 4.70 (d, J = 11.9 Hz, 1H),
4.51 (dd, J = 8.2, 2.4 Hz, 1H), 4.39 (d, J = 11.9 Hz, 1H), 4.34 (m, 1H),
3.84–3.71 (m, 3H), 3.65 (m, 1H), 3.55 (dd, J = 7.9, 6.0 Hz, 1H), 2.38 (d,
J = 1.6 Hz, 3H). 13C NMR (125 MHz, Chloroform-d)  168.96, 167.07,
155.75, 144.84, 137.75, 129.18, 128.67, 127.25, 125.81, 124.60, 121.19,
117.00, 114.90, 105.99, 78.64, 76.41, 75.12, 75.00, 70.66, 62.12, 59.23,
52.48, 19.67. HRMS (ESI+) m/z: [M + H]+ calcd for C23H26N5O6S,
500.1604; found, 500.1611.
Compound 20
1H NMR (500 MHz, Chloroform-d) 7.69–7.63 (m, 2H), 7.37–7.31
(m, 1H), 7.18 (dd, J = 8.0, 1.1 Hz, 1H), 7.11 (m, 1H), 7.01 (d, J = 2.6 Hz,
1H), 5.57 (d, J = 2.4 Hz, 1H), 4.78–4.65 (m, 2H), 4.59 (m, 1H), 4.55–
4.45 (m, 2H), 4.40 (m, 1H), 3.82 (m, 1H), 3.75–3.67 (m, 1H), 3.67–3.55
(m, 2H), 3.41 (m, 1H), 3.25 (m, 1H), 2.37 (d, J = 1.6 Hz, 3H). 13C NMR
(125 MHz, Chloroform-d)  167.07, 142.95, 136.16, 127.32, 123.25,
122.96, 121.24, 119.31, 118.29, 111.72, 111.33, 78.64, 76.41, 75.12, 75.00,
70.66, 62.12, 59.23, 50.08, 26.33, 19.67. HRMS (ESI+) m/z: [M + H]+
calcd for C21H26N5O4S, 444.1706; found, 444.1720.
Compound 21
1H NMR (500 MHz, Chloroform-d)  8.09–7.93 (m, 2H), 7.50–7.35
(m, 3H), 5.54 (d, J = 2.4 Hz, 1H), 5.46 (m, 1H), 5.24 (m, 1H), 4.73 (d, J =
11.9 Hz, 1H), 4.55–4.42 (m, 2H), 4.39 (m, 1H), 3.82–3.72 (m, 1H), 3.67
(m, 1H), 3.64–3.48 (m, 2H), 2.37 (d, J = 1.5 Hz, 3H). 13CNMR (125MHz,
Chloroform-d)  167.07, 146.50, 146.37, 137.08, 129.62, 129.23,
120.53, 120.46, 78.64, 76.41, 75.12, 75.00, 70.66, 62.12, 59.23, 52.24,
19.67. HRMS (ESI+) m/z: [M + H]+ calcd for C19H23N8O5S, 475.1512;
found, 475.1516.
Compound 22
1H NMR (500 MHz, Chloroform-d)  8.89 (d, J = 5.7 Hz, 1H), 8.51
(s, 1H), 8.10 (d, J = 5.7 Hz, 1H), 8.02 (d, J = 1.7 Hz, 1H), 7.92 (d, J = 8.6 Hz,
1H), 7.64 (dd, J = 8.4, 1.8 Hz, 1H), 5.70–5.61 (m, 1H), 4.73 (d, J = 12.1 Hz,
1H), 4.64–4.49 (m, 4H), 4.08–3.95 (m, 1H), 3.85–3.69 (m, 2H), 3.72–
3.60 (m, 1H), 3.52 (m, 1H), 2.38 (d, J = 1.5 Hz, 3H). 13C NMR (125 MHz,
Chloroform-d)  167.07, 149.26, 147.59, 147.29, 137.07, 133.72,
129.58, 127.71, 125.90, 123.65, 121.10, 108.47, 78.64, 76.41, 75.12,
75.00, 70.66, 62.12, 59.51, 19.67. HRMS (ESI+) m/z: [M + H]+ calcd for
C20H21ClN5O4S, 462.1003; found, 462.1007.
Compound 23
1H NMR (500 MHz, Chloroform-d)  7.51–7.39 (m, 3H), 7.34–7.30
(m, 2H), 6.04 (d, J = 2.5 Hz, 1H), 5.56 (s, 2H), 4.67 (d, J = 11.9 Hz, 1H),
4.62–4.51 (m, 2H), 4.35 (m, 1H), 4.11 (ddd, J = 11.9, 7.1, 5.7 Hz, 1H),
3.96 (qd, J = 5.7, 1.9 Hz, 1H), 3.79–3.67 (m, 1H), 3.61 (ddd, J = 11.9, 7.0,
5.6 Hz, 1H), 2.38 (d, J = 1.5 Hz, 3H). 13C NMR (125 MHz,
Chloroform-d)  164.19, 147.72, 146.66, 140.07, 137.07, 131.45,
122.61, 118.44, 117.66, 112.58, 77.14, 76.40, 75.00, 70.75, 62.13, 59.44,
47.15, 19.51. HRMS (ESI+) m/z: [M + H]+ calcd for C19H22ClN6O4S,
465.1112; found, 465.1122.
Compound 24
1H NMR (500MHz, Chloroform-d)  7.49 (s, 1H), 5.54 (d, J = 2.4 Hz,
1H), 4.63 (d, J = 12.1 Hz, 1H), 4.56–4.44 (m, 2H), 4.37 (tdd, J = 8.1, 6.9,
2.0 Hz, 1H), 4.07 (t, J = 6.3 Hz, 2H), 4.03–3.94 (m, 1H), 3.75–3.67 (m,
1H), 3.58 (dd, J = 7.9, 5.9 Hz, 1H), 3.56–3.41 (m, 3H), 2.35 (d, J = 1.5 Hz,
3H), 2.26–2.18 (m, 2H). 13C NMR (125 MHz, Chloroform-d)  167.07,
142.95, 122.65, 78.64, 76.41, 75.12, 75.00, 70.66, 62.12, 59.59, 59.23,
47.50, 31.54, 19.67. HRMS (ESI+) m/z: [M + H]+ calcd for C14H23N4O5S,
359.1389; found, 359.1386.
Compound 25
1H NMR (400 MHz, Chloroform-d)  7.50–7.30 (m, 2H), 7.11–6.90
(m, 2H), 3.98 (s, 4H), 3.81 (s, 2H), 3.50 (s, 2H), 1.72 (m, 4H). 13C NMR
(125 MHz, Chloroform-d)  170.77, 142.59, 133.16, 129.68, 119.40,
105.83, 64.40, 41.43, 35.21. HRMS (ESI+) m/z: [M + H]+ calcd for
C14H17N4O3, 289.1301; found, 289.1289.
Compound 26
1H NMR (400 MHz, Chloroform-d)  7.84–7.71 (m, 2H), 7.44–7.26
(m, 5H), 7.11–7.00 (m, 2H), 6.42 (s, 1H), 4.63 (d, J = 5.6 Hz, 2H).
13C NMR (125 MHz, Chloroform-d)  167.51, 142.34, 138.68, 131.26,
128.98, 128.40, 127.31, 127.17, 119.27, 43.74. HRMS (ESI+) m/z: [M +
H]+ calcd for C14H13N4O, 253.1090; found, 253.1094.
Compound 27
1H NMR (500 MHz, Chloroform-d)  7.99–7.79 (m, 2H), 7.35 (t, J =
4.3 Hz, 1H), 7.25–7.22 (m, 2H), 3.47 (qd, J = 7.1, 4.3 Hz, 2H), 1.23 (t, J =
7.1 Hz, 3H). 13C NMR (125 MHz, Chloroform-d)  167.51, 142.45,
130.86, 128.98, 119.27, 35.96, 14.66. HRMS (ESI+) m/z: [M + H]+ calcd
for C9H11N4O, 191.0933; found, 191.0925.
Compound 28
1H NMR (400 MHz, Chloroform-d)  7.92–7.71 (m, 2H), 7.22–6.98
(m, 2H), 6.15 (s, 1H), 3.47 (td, J = 7.2, 5.7 Hz, 2H), 1.69–1.59 (m, 2H),
1.60–1.34 (m, 2H), 0.98 (t, J = 7.3 Hz, 3H). 13C NMR (125 MHz,
Chloroform-d)  168.71, 142.34, 130.79, 128.98, 119.27, 40.10, 30.74,
20.43, 13.74. HRMS (ESI+) m/z: [M + H]+ calcd for C11H15N4O,
219.1246; found, 219.1239.
Compound 29
1H NMR (400 MHz, Chloroform-d)  7.82–7.66 (m, 2H), 7.27 (d, J =
3.2 Hz, 2H), 7.26–7.17 (m, 3H), 7.11–6.98 (m, 2H), 6.28 (d, J = 7.5 Hz,
1H), 4.94 (qt, J = 7.2, 4.3 Hz, 1H), 3.42 (dd, J = 16.2, 7.1 Hz, 2H), 2.92
(dd, J = 16.2, 4.4 Hz, 2H). 13C NMR (100MHz, Chloroform-d)  170.53,
142.40, 138.27, 133.26, 129.34, 128.70, 127.77, 127.41, 119.43, 51.72,
35.93. HRMS (ESI+) m/z: [M + H]+ calcd for C15H15N4O, 267.1246;
found, 267.1256.
Results and discussion
The sensitivity of the thiazoline ring of NAG-thiazoline limits
the conditions to which this molecule can be subjected, which in
turn circumscribes those chemical transformations that can be
used to derivatize this compound. For example, in acidic condi-
tions (pH < 6.0), thiazolines are protonated to form an easily hy-
drolyzed thiazolinium;38 in oxidative conditions, the sulfur can
be oxidized; and in reductive or radical conditions, the N=C dou-
ble bond can be degraded.37 Thus, mild protection and deprotec-
tion conditions are required. Based on these considerations, we
developed a convenient route using selective pivaloylation of
NAG-thiazoline at the 3- and 6-hydroxyl groups (Scheme 1). Nota-
bly, we ultimately settled on this bulky protecting group after a
range of silyl- and ether-based protecting groups were explored,
none of which proved suitable. We were surprised by the com-
plete lack of regioselectivity between the 3- and 4-positions during
selective pivaloylation despite our exploring a range of different
conditions. Nevertheless, we could readily recycle undesired
by-products back to NAG-thiazoline using methanolic sodium
methoxide. This approach allowed for large-scale synthesis of
selectively protected 2, which we propargylated through the ad-
dition of base at low temperatures to yield 5. The regioselectivity
of pivaloylation was confirmed by analysis of HMBC NMR data.
Specifically, the quaternary pivaloyl 13C signals (178.21 and 178.23
in 2, 178.25 and 177.28 in 5) were found to strongly correlate with
the H-3 and H-6 1H resonances. Finally, global deprotection of the
pivaloyl protecting groups yielded the advanced common inter-
mediate 6. The structure of 6, as opposed to other regioisomers,
was supported by comparison of the 1HNMR spectra of compound
6 with the NAG-thiazoline, which showed the by far most pro-
nounced chemical shits in the resonances for H-4 (0.24 ppm) and
C-4 (4 ppm), whereas all other resonances of the pyranose ring
differed by approximately 0.1 ppm for 1H data and 2 ppm for 13C.
Last step derivatization of this intermediate enabled us to rapidly
prepare a targeted panel of candidate inhibitors via click CuAAC
chemistry.40 Although CuAAC chemistry has been well studied
and shown to be compatible with a wide range of functional
groups, we observed that the thiazoline moiety of NAG-thiazoline
greatly impaired this coupling reaction. For this reason, we re-
sorted to stabilizing the cuprous ion using added ligands, which
we expectedwould protect against poisoning of the catalyst by the
thiazoline moiety. In this regard, we found that BTTAA, a tris-
triazole ligand used to catalyze the CuAAC reaction in conditions
of low copper (I) in vivo and live cell environments41,42 worked
efficiently in our hands for this purpose (Scheme 1; Table 1). Using
this strategy, we were able to conveniently prepare a panel of
18 compounds as potential GH18 and GH85 inhibitors. The success
of targeted libraries of inhibitors in which carbohydrate core
structures have been derivatized in various ways has proven to be
of use in finding high affinity ligands for Siglecs43 and hexosamin-
dases.44 Accordingly, we anticipate this small panel of com-
pounds, as well as larger libraries generated using our strategy,
should prove useful for those interested in identifying inhibitors
of various classes of enzymes using substrate-assisted catalysis.
Testing these compounds against various enzymes is a future
topic being pursued, and results from these studies will be re-
ported in due course.
Conclusion
We have developed a route to create targeted panels of deriva-
tized NAG-thiazolines as potential inhibitors of GH18 and GH85
enzymes. This strategy relied of selective protection of NAG-
thiazoline followed by propargylation and deprotection to yield a
late stage common intermediate. CuAAC reaction, using BTTAA as
a protective ligand and catalyst, enabled the rapid generation of a
library of potential inhibitors. These compounds, as hybrid tran-
sition state medicinal chemistry like compounds, may serve as
leads to obtain useful inhibitors that could be used to both further
our fundamental understanding regarding the roles of these en-
zymes, as well as help validate inhibition of these enzymes as a
viable strategy to treat diseases. Examples of enzymes of high
interest for which inhibitors may have therapeutic potential in-
clude human ENGase, inhibition of which may be valuable for
protecting against the deleterious effects associated with loss of
NGLY1,45,46 as well as several known bacterial virulence factors,
including Endohexosaminidase D (GH85),47,32 Auto (GH73),48 and
peptidoglycan hydrolase FlgJ (GH73).49,50
Scheme 1. Synthesis of divergent intermediate 6 and generation of a targeted panel of inhibitors.
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